Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy

Completed · Phase 3

Conditions studied: Contraception

In brief

The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.

Key facts

Study ID

NCT04756037

Run by

Sumitomo Pharma Switzerland GmbH

People needed

1164

Starts

2021-03-18

Expected to finish

2026-03-31

Last updated by the study team

2026-05-13

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Chandler — Chandler, Arizona, United States
• Mesa — Mesa, Arizona, United States
• Peoria — Peoria, Arizona, United States
• Phoenix — Phoenix, Arizona, United States
• Burbank — Burbank, California, United States
• Canoga Park — Canoga Park, California, United States
• Encinitas — Encinitas, California, United States
• Gardena — Gardena, California, United States
• Lancaster — Lancaster, California, United States
• Long Beach — Long Beach, California, United States
• Long Beach — Long Beach, California, United States
• Palo Alto — Palo Alto, California, United States
• Sacramento — Sacramento, California, United States
• San Diego — San Diego, California, United States
• San Fernando — San Fernando, California, United States
• Valley Village — Valley Village, California, United States
• West Covina — West Covina, California, United States
• Aurora — Aurora, Colorado, United States
• Greenwood Village — Greenwood Village, Colorado, United States
• Washington — Washington D.C., District of Columbia, United States
• Washington — Washington D.C., District of Columbia, United States
• Aventura — Aventura, Florida, United States
• Boynton Beach — Boynton Beach, Florida, United States
• Davie — Davie, Florida, United States
• Mobile — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.